Guidelines for the management of ulcerative colitis. Recommendations of the working group of the polish national consultant in gastroenterology and the polish society of gastroenterology;Wytyczne grupy roboczej konsultanta krajowego w dziedzinie gastroenterologii i polskiego towarzystwa gastroenterologii dotyczace postepowania z pacjentem z wrzodziejacym zapaleniem jelita grubego

Przeglad Gastroenterologiczny

Volumn 8, Issue 1, 2013, Pages 1-20

  Eder, Piotr ^a   Łodyga, Michal ^b   Łykowska Szuber, Liliana ^a   Bartnik, Witold ^c   Durlik, Marek ^d   Gonciarz, Maciej ^e   Kłopocka, Maria ^f   Linke, Krzysztof ^a   Małecka Panas, Ewa ^g   Radwan, Piotr ^h   Rydzewska, Grazyna ^b  

^a Katedra I Klinika Gastroenterologii   (Poland)

^b Leczenia Nieswoistych Chorób Zapalnych Jelit Centralnego Szpitala Klinicznego MSW   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d Klinika Chirurgii Gastroenterologicznej I Transplantologii Centralnego Szpitala Klinicznego MSW   (Poland)

^e Wojewodzkiego Szpitala Specjalistycznego Im sW Barbary ^*  (Poland)

^f NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^g MEDICAL UNIVERSITY OF LODZ   (Poland)

^h Uniwersytetu Medycznego   (Poland)

Author keywords

Anti TNF; Endoscopy; Mesalazine; Thiopurines; Ulcerative colitis

Indexed keywords

ARTICLE; MEDICAL SOCIETY; PRACTICE GUIDELINE; ULCERATIVE COLITIS;

EID: 84878410732     PISSN: 18955770     EISSN: 18974317     Source Type: Journal    
DOI: 10.5114/pg.2013.34176     Document Type: Article

References (142)

1. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 3: 1606-19.
2. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006; 12: 6102-8.
3. Bartnik W. Wytyczne postepowania w nieswoistych chorobach zapalnych jelit. Prz Gastroenterol 2007; 2: 215-29.
4. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365: 1713-25.
5. Łodyga M, Eder P, Bartnik W i wsp. Wytyczne Grupy Roboczej Konsultanta Krajowego w dziedzinie Gastroenterologii i Polskiego Towarzystwa Gastroenterologii dotyczace postepowania z pacjentem z choroba Lesniowskiego-Crohna. Prz Gastroenterol 2012; 7: 317-38.
6. Dignass A, Eliakim R, Magro F, et al. Second European evidencebased consensus on the diagnosis and management of ulcerative colitis. Part 1: definitions and diagnosis. J Crohns Colitis 2012; 6: 965-90.
7. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence- based consensus on the diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2012; 6: 991-1030.
8. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: special situations. J Crohns Colitis 2013; 7: 1-33.
9. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A): 5-36.
10. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
11. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86.
12. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27.
13. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11.
14. Travis SP, Jewell DP. Ulcerative colitis: clinical presentation and diagnosis. In: Inflammatory bowel diseases. Satsangi J, Sutherland LR (eds.). Churchill Livingstone 2003; 169-81.
15. Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol 2005; 3: 11-4.
16. Pera A, Bellando P, Caldera D, et al. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology 1987; 92: 181-5.
17. Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012; 61: 535-42.
18. Cooney RM, Warren BF, Altman DG, et al. Outcome measurement in clinical trials for ulcerative colitis towards standardisation. Trials 2007; 8: 17.
19. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012; 61: 1619-35.
20. Schumacher G, Kollberg B, Sandstedt B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Histologic course during the 1st year after presentation. Scand J Gastroenterol 1994; 29: 318-32.
21. Seldenrijk CA, Morson BC, Meuwissen SG, et al. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. Gut 1991; 32: 1514-20.
22. Cook MG, Dixon MF. An analysis of the reliability of detection and diagnostic value of various pathological features in Crohn's disease and ulcerative colitis. Gut 1973; 14: 255-62.
23. Odze R, Antonioli D, Peppercorn M, et al. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol 1993; 17: 869-75.
24. Kleer CG, Appelman HD. Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. Am J Surg Pathol 1998; 22: 983-9.
25. Rice-Oxley JM, Truelove SC. Ulcerative colitis course and prognosis. Lancet 1950; 255: 663-6.
26. Fenner L, Widmer A, Goy G, et al. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol 2008; 46: 328-30.
27. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642-7.
28. Minami M, Ohta M, Ohkura T, et al. Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. World J Gastroenterol 2007; 13: 754-60.
29. Ajaj WM, Lauenstein TC, Pelster G, et al. Magnetic resonance colonography for the detection of inflammatory diseases of the large bowel: quantifying the inflammatory activity. Gut 2005; 54: 257-63.
30. Schreyer AG, Scheibl K, Heiss P, et al. MR colonography in inflammatory bowel disease. Abdom Imaging 2006; 31: 302-7.
31. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20.
32. Leo S, Leandro G, Di Matteo G, et al. Ulcerative colitis in remission: it is possible to predict the risk of relapse? Digestion 1989; 44: 217-21.
33. Bitton A, Sewitch MJ, Peppercorn MA, et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol 2003; 98: 2203-8.
34. Vidal A, Gomez-Gil E, Sans M, et al. Life events and inflammatory bowel disease relapse: a prospective study of patients enrolled in remission. Am J Gastroenterol 2006; 101: 775-81.
35. Riley SA, Mani V, Goodman MJ, Lucas S. Why do patients with ulcerative colitis relapse? Gut 1990; 31: 179-83.
36. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-201.
37. Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15: 1190-8.
38. Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010 1: CD004115.
39. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 601-16.
40. Regueiro M, Loftus Jr EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006; 12: 979-94.
41. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: 960-5.
42. Bokemeyer B, Hommes D, Gill I, et al. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. J Crohns Colitis 2012; 6: 476-82.
43. Flourle B, Hagege H, Tucat G, et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. 7th Congress of ECCO, Barcelona, Spain, February 16- 18, 2012, abstract No 183. J Crohns Colitis 2012; 6 (Suppl 1): S82.
44. Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005; 21: 1111-9.
45. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 762-9.
46. Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009; 104: 2760-7.
47. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007: 1: CD000478.
48. Mate-Jimenez J, Hermida C, Cantero-Perona J, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 1227-33.
49. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53.
50. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
51. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; 3: CD005112.
52. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-7.
53. Reinisch W, Sandborn WJ, Kumar A, et al. 52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. J Crohns Colitis 2011; 5: 10.
54. Van Assche G, Vermeire S, Rutgeerts P. Management of acute severe ulcerative colitis. Gut 2011; 60: 130-3.
55. Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 1990; 12: 40-1.
56. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103-10.
57. Randall JSB, Warren BF, Travis SP, et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg 2010; 97: 404-9.
58. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-9.
59. Van Assche G, D'Haens G, Noman M, et al. Randomized, doubleblind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-31.
60. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo controlled study. Gastroenterology 2005; 128: 1805-11.
61. Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007; 26: 411-9.
62. Sjöberg M, Walch A, Meshkat M, et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis 2011; 18: 212-8.
63. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-15.
64. Benazzato L, D'Inca R, Grigoletto F, et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004; 36: 461-6.
65. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
66. Loftus CG, Loftus EV, Sandborn WJ. Cyclosporin for refractory ulcerative colitis. Gur 2003; 52: 172-3.
67. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008; 2: 219-25.
68. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
69. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54.
70. Leblanc S, Allez M, Seksik P, et al. Successive treatment with cyclosporine and infliximab in severe ulcerative colitis (UC). Am J Gastroenterol 2011; 106: 771-7.
71. Alves A, Panis Y, Bouhnik Y, et al. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg 2003; 197: 379-85.
72. Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum 2005; 48: 70-3.
73. Richards DM, Hughes SA, Irving MH, Scott NA. Patient quality of life after successful restorative proctocolectomy is normal. Colorectal Dis 2001; 3: 223-6.
74. Tekkis PP, Fazio VW, Lavery IC, et al. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. Ann Surg 2005; 241: 262-8.
75. Gorgun E, Remzi FH, Goldberg JM, et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery 2004; 136: 795-803.
76. Lake JP, Firoozmand E, Kang JC, et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J Gastrointest Surg 2004; 8: 547-51.
77. Subramanian V, Saxena S, Kang JY, et al. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 2008; 103: 2373-81.
78. Mahadevan U, Loftus Jr EV, Tremaine WJ, et al. Azathioprine or 6- mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002; 8: 311-6.
79. Yang Z, Wu Q, Wu K, Fan D. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 2010; 31: 486-92.
80. Coquet-Reinier B, Berdah SV, Grimaud JC, et al. Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis: a case-matched study. Surg Endosc 2010; 24: 1866-71.
81. Rizzo G, Armuzzi A, Pugliese D, et al. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. Int J Colorectal Dis 2011; 26: 1435-44.
82. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995; 222: 120-7.
83. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994; 107: 1856-60.
84. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-9.
85. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-14.
86. Calabrese C, Gionchetti P, Rizzello F, et al. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment Pharmacol Ther 2008; 27: 759-64.
87. Barreiro-de Acosta M, Garcia-Bosch O, Gordillo J, et al. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol 2012; 24: 756-8.
88. Baars JE, Looman CW, Steyerberg EW, et al. The risk of inflammatory bowel disease related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 2010; 106: 319-28.
89. Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004; 2: 1088-95.
90. Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50: 158-64.
91. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005; 54: 1573-8.
92. Terdiman JP, Steinbuch M, Blumentals WA, et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 367-71.
93. Vermeire S, Carbonnel F, Coulie PG, et al. Management of inflammatory bowel disease in pregnancy. J Crohns Colitis 2012; 6: 811-23.
94. Andrews JM, Mountifield RE, Van Lengenberg DR, et al. Unprompted issues in inflammatory bowel disease: opportunities to optimize care. Intern Med J 2010; 40: 173-82.
95. Mountfield R, Bampton P, Prosser R, et al. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis 2009; 15: 720-5.
96. Gorgun E, Remzi FH, Goldberg JM, et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anastomosis: a study of 300 patients. Surgery 2004; 136: 795-803.
97. Toovey S, Hudson S, Hendry WF, et al. Sulphasalazine and male fertility: reversibility and possible mechanisms. Gut 1981; 22: 445-51.
98. Toth A. Reversible toxic effect of salicylazosulfapyridine on semen quality. Fertil Steril 1979; 31: 538-40.
99. Moskovitz DN, Bodian C, Chapman ML, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004; 99: 656-61.
100. Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defect. N Engl J Med 2000; 343: 1608-14.
101. Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008; 25: 271-5.
102. Hernandez-Diaz S, Mitchell AA, Kelley KE, et al. Medications as a potential source of exposure to phtalates in the U.S. population. Environ Health Perspect 2009; 117: 185-9.
103. Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazol treatment during pregnancy. Br J Obstet Gynaecol 1998; 105: 322-7.
104. Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995; 172: 525-9.
105. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemoter 1998; 42: 1336-9.
106. Park-Wylie JD. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385-92.
107. Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011; 106: 214-23.
108. Ostensen M, Forger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol 2009; 5: 382-90.
109. Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol 2009; 85: 647-54.
110. Rajapakse RO, Korelitz BI, Zlatanic J, et al. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 2000; 95: 684-8.
111. Langagergaard V, Pedersen L, Gislum M, et al. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther 2007; 25: 73-81.
112. Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011; 60: 198- 203.
113. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009; 36: 635-41.
114. Mahadevan U, Kane S. Use of infliximab in pregnancy. Am J Gastroenterol 2010; 105: 219-20.
115. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidencebased consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
116. Cheent K, Nolan J, Shariq S, et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010; 4: 603-5.
117. Rahier JF, Moutschen M, Van Gompel A, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010; 49: 1815-27.
118. Ostensen M, Hartmann H, Salvesen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol 2000; 27: 1872-5.
119. Ostensen M, Motta M. Therapy insight: the use of antirheumatic drugs during nursing. Nat Clin Pract Rheumatol 2007; 3: 400-6.
120. Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008; 28: 1209-13.
121. Brandt LJ, Estabrook SG, Reinus JF. Results of a survey to evaluate whether vaginal delivery and episiotomy lead to perianal involvement in women with Crohn's disease. Am J Gastroenterol 1995; 90: 1918-22.
122. Reinshagen M. Osteoporosis in inflammatory bowel disease. J Crohns Colitis 2008; 2: 202-7.
123. Trost LB, McDonnel JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005; 81: 580-5.
124. Requena L, Sanchez Yus E. Erythema nodosum. Semin Cutan Med Surg 2007; 26: 114-25.
125. Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol 2006; 31: 823-4.
126. Torzecka JD, Kondras K, Dziankowska-Bartkowiak B, et al. Piodermia zgorzelinowa - interdyscyplinarny problem diagnostyczny. Pol Merkur Lekarski 2008; 24: 34-7.
127. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006; 333: 181-4.
128. Brooklyn TN, Dunnill MGS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut 2006; 55: 505-9.
129. Poritz LS, Lebo MA, Bobb AD, et al. Management of peristomal pyoderma gangrenosum. J Am Coll Surg 2008; 206: 311-5.
130. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42: 387-91.
131. Fornaciari G, Salvarani C, Beltrami M, et al. Musculoskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001; 15: 399-403.
132. Bonner GF, Fakhri A, Vennamanen SR. A long-term cohort study of non-steroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 751-7.
133. Dougados M, Van der Linden S, Leirisalo-Repo M. Sulfasalazine in the treatment of spondyloarthropathy. A randomized multicenter, double-blind placebo controlled study. Arthritis Rheum 1995; 38: 618-27.
134. De Vlam K, Mielants H, Cuvelier C, et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000; 27: 2860-5.
135. Gorman J, Sack K, Davis J. Treatment of active ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349-56.
136. Vitellas KM, Enns RA, Keogan MT, et al. Comparison of MR cholangiopancreatographic techniques with contrast-enhanced cholangiography in the evaluation of sclerosing cholangitis. AJR Am J Roentgenol 2002; 178: 327-34.
137. Talwalkar JA, Angulo P, Johnson CD, et al. Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004; 40: 39-45.
138. Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of highdose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121: 900-7.
139. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-14.
140. Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999; 29: 1050-6.
141. Stawczyk-Eder K, Eder P, Łykowska-Szuber L i wsp. Strategia szczepien w nieswoistych zapaleniach jelit. Gastroenterol Prakt 2010; 3: 64-8.
142. Tourner M, Loftus Jr EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36.